Intravenous Levodopa ( DrugBank: Levodopa )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 4 |
6. パーキンソン病
臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00605553 (ClinicalTrials.gov) | April 2008 | 15/1/2008 | Study to Evaluate SYN115 in Parkinson's Disease | A Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Study to Explore the Effects of 7 Days of Dosing With SYN115 20 mg p.o. BID or 60 mg p.o. BID on Clinical and fMRI Response to Intravenous Levodopa in Patients With Mild to Moderate Parkinson's Disease | Parkinson's Disease | Drug: Placebo;Drug: Tozadenant | Biotie Therapies Inc. | NULL | Completed | 40 Years | 75 Years | All | 30 | Phase 2 | United States |
2 | NCT00089622 (ClinicalTrials.gov) | August 4, 2004 | 6/8/2004 | Lisuride Patch to Treat Parkinson's Disease | Transcutaneous Lisuride Therapy of Parkinson's Disease | Parkinson Disease | Drug: Intravenous Levodopa;Drug: Lisuride Transdermal System | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | 40 Years | 80 Years | All | 40 | Phase 2 | United States |
3 | NCT00086294 (ClinicalTrials.gov) | June 25, 2004 | 29/6/2004 | ACP-103 to Treat Parkinson's Disease | 5HT2A/C Serotonin Blockade in Parkinson's Disease | Parkinson's Disease;Dyskinesias | Drug: Intravenous Levodopa;Drug: ACP-103 | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | 30 Years | 80 Years | All | 40 | Phase 2 | United States |
4 | NCT00076674 (ClinicalTrials.gov) | January 2004 | 28/1/2004 | Levetiracetam Treatment of L-dopa Induced Dyskinesias | Levetiracetam Treatment of L-dopa Induced Dyskinesias | Dyskinesias;Parkinson Disease | Drug: Intravenous Levodopa | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 40 | Phase 2 | United States |